Loading
A phase 1/2 trial of Lenalidomide in follicular lymphoma, run by Beijing Mabworks Biotech Co., Ltd., now recruiting.
MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL) is a phase 1/2 interventional study registered as NCT04110301 by Beijing Mabworks Biotech Co., Ltd., with 53 participants planned, started 2019-11-28 and due to reach its primary completion in 2024-01-09. Interventions recorded: Recombinant Humanized Monoclonal Antibody MIL62 Injection, Lenalidomide. Conditions listed: Follicular Lymphoma and Marginal Zone Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Follicular lymphoma.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Follicular lymphoma.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation).
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Follicular lymphoma.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation).
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Follicular lymphoma.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Follicular lymphoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/